LifeVantage (LFVN) Q2 2026 earnings review
Growth Engine Stalls: Revenue Plunges 28%, CEO Retires, Guidance Slashed
LifeVantage faced a reckoning in Q2. Cycling the massive launch of its MindBody GLP-1 System from a year ago, the company failed to sustain momentum. Revenue collapsed 27.8% YoY to $48.9 million, with the critical Americas region down nearly 33%. The deterioration forced a massive cut to full-year guidance and coincided with the announcement that CEO Steve Fife will retire in April 2026. An inventory obsolescence charge of $2.4M for the GLP-1 product confirms demand fell far faster than management anticipated.
🐂 Bull Case
Despite the operational miss, the balance sheet remains pristine with $10.2 million in cash and zero debt. The company continues to return capital, declaring a dividend and approving a new $60 million share repurchase program.
The LoveBiome acquisition is fully integrated and expanding the portfolio into the high-growth microbiome category. New product launches planned for upcoming quarters could help stabilize the topline.
🐻 Bear Case
The Americas region—LifeVantage's engine—saw revenue evaporate by 32.6% YoY. Active Customers in the region fell from 80,000 to 54,000 (-32.5%), indicating a mass exodus of users recruited during the initial GLP-1 hype.
A $2.4 million inventory obsolescence charge for the MindBody GLP-1 System is a glaring red flag. It signals that production vastly exceeded actual sell-through, severely compressing gross margins.
⚖️ Verdict: 🔴🔴
Strong Sell. The company is shrinking rapidly as the GLP-1 weight loss narrative unwinds. With revenue down ~28%, a leadership vacuum incoming, and a massive guidance cut, the investment thesis is broken until a floor is established.
Key Themes
Americas Customer Exodus
The Americas region is in freefall. Active Customers dropped by 26,000 YoY (-32.5%), and Active Independent Consultants fell 8.6%. The company is failing to retain the wave of users acquired during the Q2 FY25 product launch.
MindBody GLP-1 Product Failure
The MindBody System was the sole driver of growth last year (+31% in 25Q2). In 26Q2, it became a liability. The company took a $2.4 million write-off for obsolete inventory, dragging GAAP Gross Margin down to 74.0% from 80.5%. This confirms that the 'weight loss' boom was transient and demand has cratered.
Leadership Uncertainty
CEO Steve Fife announced his retirement effective April 2026. While a succession plan is mentioned, a leadership change during a period of double-digit revenue decline and strategy realignment adds significant execution risk.
Capital Return Strategy
Management is using the balance sheet to defend the stock. A new $60 million repurchase authorization replaces the old one, and a $0.045 dividend was declared. However, buying back stock while revenue shrinks 28% is a risky allocation of capital.
International Stability
While the Americas collapsed, Asia/Pacific & Europe held up relatively well, down only 2.1% (3.7% constant currency). This segment is becoming a larger portion of the pie by default, but cannot offset the domestic losses.
Cost Control
SG&A expenses decreased to $15.8 million from $18.6 million YoY. However, due to the sharp revenue drop, SG&A as a percentage of revenue actually deleveraged, rising to 32.3% from 27.5%.
Other KPIs
Reversing. Down 27.8% YoY. A stark contrast to the +31% growth seen in the prior year period. The cyclicality of the weight-loss product launch proved to be a massive headwind.
Decelerating. Down from $6.5 million in the prior year. Margin compressed to 8.0% from 9.6% as fixed costs weighed heavier on a smaller revenue base.
Stable. Down from $20.2 million at fiscal year-end (June 30), reflecting cash used for the LoveBiome acquisition and operations. Zero debt remains a key anchor.
Guidance
Reversing. This is a massive cut from the prior guidance of $225-$240 million issued just last quarter. The implied midpoint ($192.5M) represents a ~16% decline from FY25 revenue of $228.5M.
Decelerating. Cut significantly from the prior range of $23-$26 million. The new midpoint ($17M) implies a ~23% drop from FY25's $22.1M result.
Decelerating. Lowered from prior guidance of $1.00-$1.15. Comparison: FY25 Adjusted EPS was $0.82. The company now expects earnings contraction YoY.
Key Questions
MindBody Inventory Reality
You took a $2.4M obsolescence charge on MindBody just one year after launch. Does this indicate the product has reached end-of-life, or is there a viable path to stabilize demand?
Americas Recovery Plan
With Americas revenue down 33% and active customers down 32%, what specific actions beyond 'redoubling efforts' will stop the bleeding in the core market?
CEO Succession Timeline
With Steve Fife leaving in April, how far along is the search process, and is the Board prioritizing an internal candidate or an external turnaround expert?